Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal microcircuits constrain the generation of epileptiform activity.

bioRxiv : the preprint server for biology·2026
Same author

Cortical stimulation reveals effective disconnection of the epileptogenic network at seizure onset.

Epilepsia·2026
Same author

Hippocampal Long Axis Differentiation in Memory and Seizure Networks.

Epilepsy currents·2026
Same author

Dentate gyrus interneurons modulate winner-take-all network dynamics in freely behaving mice.

Neuron·2026
Same author

Intrinsic and extrinsic connectivity of the seizure onset zone at rest and during stimulation.

medRxiv : the preprint server for health sciences·2026
Same author

Low Frequency Stimulation and Seizure Induction in Pediatric and Young Adult Patients With Drug Resistant Epilepsy Undergoing Stereoelectroencephalography.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2026

Related Experiment Video

Updated: Jun 22, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Pursuing paradoxical proconvulsant prophylaxis for epileptogenesis.

Caren Armstrong1, Robert J Morgan, Ivan Soltesz

  • 1Department of Anatomy and Neurobiology, University of California, Irvine, California, USA. cmarmstr@uci.edu

Epilepsia
|June 26, 2009
PubMed
Summary

Cannabinoid antagonists may offer a new way to prevent acquired epilepsy. While initially causing seizures, these drugs show promise for long-term protection against hyperexcitability after brain injury.

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Related Experiment Videos

Last Updated: Jun 22, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epileptology

Background:

  • Acquired epilepsies lack effective prophylactic treatments.
  • Existing antiepileptic drugs are often ineffective for established acquired epilepsies.
  • Developing preventative strategies for acquired epilepsy is complex.

Purpose of the Study:

  • To review research on cannabinoid drugs for acquired epilepsy prevention.
  • To explore the potential of cannabinoid antagonists as prophylactic agents.
  • To discuss challenges and future directions in epilepsy prevention.

Main Methods:

  • Literature review of cannabinoid research in the context of central nervous system (CNS) hyperexcitability and seizures.
  • Analysis of acute versus long-term effects of cannabinoid modulators.
  • Discussion of implications for prophylactic treatment strategies.

Main Results:

  • Cannabinoid antagonists, though acutely proconvulsant, may reduce long-term hyperexcitability.
  • This suggests potential prophylactic benefits against acquired epilepsy following various brain insults.
  • The research highlights a potential shift from traditional anticonvulsants to novel preventative approaches.

Conclusions:

  • Cannabinoid antagonists represent a promising avenue for acquired epilepsy prophylaxis.
  • Future strategies may require targeting specific time windows post-insult.
  • Moving beyond conventional anticonvulsants is crucial for developing effective preventative treatments for acquired epilepsy.